Cardiol Therapeutics
CRDL
47 hedge funds and large institutions have $37.6M invested in Cardiol Therapeutics in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 9 closing their positions.
333% more capital invested
Capital invested by funds: $8.69M → $37.6M (+$28.9M)
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
15.8% more ownership
Funds ownership: 9.15% → 24.95% (+16%)
15% more funds holding
Funds holding: 41 → 47 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$15.5M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$841K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$816K |
| 5 |
Renaissance Technologies
New York
|
+$236K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$570K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$350K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$144K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$137K |
| 5 |
Morgan Stanley
New York
|
-$96.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Simplex Trading
Chicago,
Illinois
| – | -$33K | -32,197 | Closed |
|
52
Two Sigma Advisers
New York
| – | -$18.2K | -19,100 | Closed |
|
53
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
| – | -$16.6K | -16,552 | Closed |
|
|
NA
54
NewEdge Advisors
New Orleans,
Louisiana
| – | -$4.77K | -5,000 | Closed |
|
|
DEM
55
Disciplined Equity Management
Neptune Beach,
Florida
| – | -$605 | -500 | Closed |
|
|
OC
56
Optima Capital
Beaverton,
Oregon
| – | -$27 | -28 | Closed |
|
CRDL Hedge Fund Activity: Q1 2026 in Review
47 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q1 2026, worth a combined $37.6M — up 333% from $8.69M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CRDL positions and 9 closed out — a net gain of 6 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was MMCAP International, adding an estimated $15.5M. The largest seller was AdvisorShares Investments, exiting entirely with an estimated $570K sold.
- 47 institutional investors held Cardiol Therapeutics (CRDL) as of Q1 2026, up from 41 in Q4 2025.
- Funds reported $37.6M of Cardiol Therapeutics stock for Q1 2026, up 333% quarter-over-quarter.
- 15 funds opened new Cardiol Therapeutics positions in Q1 2026 and 9 closed out, a net change of +6 holders.
- The largest Cardiol Therapeutics buyer in Q1 2026 was MMCAP International, an estimated $15.5M added.
- The largest Cardiol Therapeutics seller in Q1 2026 was AdvisorShares Investments, an estimated $570K sold.
Based on aggregated 13F filings for Q1 2026.